Annandale Capital, LLC Uro Gen Pharma Ltd. Transaction History
Annandale Capital, LLC
- $714 Million
- Q3 2024
A detailed history of Annandale Capital, LLC transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Annandale Capital, LLC holds 75,552 shares of URGN stock, worth $837,116. This represents 0.13% of its overall portfolio holdings.
Number of Shares
75,552
Previous 75,552
-0.0%
Holding current value
$837,116
Previous $1.27 Million
24.29%
% of portfolio
0.13%
Previous 0.22%
Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$42 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$41.4 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$25.5 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$24.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$24.2 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $252M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...